HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post Pumps Up Nutrition Activity With Nestle’s PowerBar, Musashi Brands

This article was originally published in The Tan Sheet

Executive Summary

The cereal giant is bulking up its Active Nutrition Group and targeting annualized revenues of $550 million in the nutrition and weight loss sector. Post also continues diversifying its revenues with the deal.

You may also be interested in...



Cereal Firm Post Expands Into Supplements With Premier Nutrition Pick-Up

Seeking to diversify its portfolio for more dramatic sales growth, Post Holdings acquires Premier Nutrition, maker of Joint Juice and Premier Protein supplements. The $180 million transaction follows closely Post’s purchase of probiotic bar and natural cereal maker Attune Foods.

Nestle China JV Backs Nutritional And Rx Botanical Development

Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.

Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio

Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel